Free Trial

Sumitomo Mitsui Trust Group Inc. Has $139.44 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics logo with Medical background

Sumitomo Mitsui Trust Group Inc. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,968,034 shares of the company's stock after selling 183,480 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 3.49% of CRISPR Therapeutics worth $139,438,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in CRSP. ProShare Advisors LLC increased its holdings in CRISPR Therapeutics by 10.1% during the 1st quarter. ProShare Advisors LLC now owns 5,791 shares of the company's stock valued at $395,000 after acquiring an additional 530 shares in the last quarter. Entropy Technologies LP purchased a new position in shares of CRISPR Therapeutics in the 1st quarter worth $1,723,000. Blair William & Co. IL lifted its holdings in CRISPR Therapeutics by 8.2% in the 1st quarter. Blair William & Co. IL now owns 147,890 shares of the company's stock worth $10,080,000 after buying an additional 11,190 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of CRISPR Therapeutics by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company's stock valued at $111,564,000 after buying an additional 46,148 shares during the last quarter. Finally, Orion Capital Management LLC grew its holdings in CRISPR Therapeutics by 44.0% during the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company's stock worth $49,000 after acquiring an additional 220 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 30,000 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now directly owns 196,540 shares of the company's stock, valued at approximately $10,931,554.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 30,000 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the sale, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,382 shares of company stock valued at $1,917,679 over the last three months. 4.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

CRSP has been the topic of several recent research reports. Truist Financial cut their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating on the stock in a research report on Monday, August 12th. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a "buy" rating on the stock in a research note on Tuesday, August 6th. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a "buy" rating and a $90.00 price objective for the company. Barclays dropped their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a report on Wednesday, November 6th. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $74.94.

Get Our Latest Analysis on CRISPR Therapeutics

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded down $0.94 during trading hours on Wednesday, hitting $49.79. The company had a trading volume of 1,861,343 shares, compared to its average volume of 1,470,891. The firm's fifty day moving average is $47.80 and its 200-day moving average is $52.12. CRISPR Therapeutics AG has a fifty-two week low of $43.42 and a fifty-two week high of $91.10. The firm has a market capitalization of $4.25 billion, a P/E ratio of -17.59 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the previous year, the firm posted ($1.41) earnings per share. Analysts anticipate that CRISPR Therapeutics AG will post -5.2 earnings per share for the current year.

CRISPR Therapeutics Company Profile

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Should you invest $1,000 in CRISPR Therapeutics right now?

Before you consider CRISPR Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.

While CRISPR Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?
These Top Stocks in 2024 Will Continue to be Big Winners in 2025
’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines